» Articles » PMID: 19307988

Suppressive Influences in the Immune Response to Cancer

Overview
Journal J Immunother
Date 2009 Mar 25
PMID 19307988
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Although much evidence has been gathered demonstrating that immune effectors can play a significant role in controlling tumor growth under natural conditions or in response to therapeutic manipulation, it is clear that malignant cells do evade immune surveillance in most cases. Considering that anticancer active specific immunotherapy seems to have reached a plateau of results and that currently no vaccination regimen is indicated as a standard anticancer therapy, the dissection of the molecular events underlying tumor immune escape is the necessary condition to make anticancer vaccines a therapeutic weapon effective enough to be implemented in the routine clinical setting. Recent years have witnessed significant advances in our understanding of the molecular mechanisms underlying tumor immune escape. These mechanistic insights are fostering the development of rationally designed therapeutics aimed to revert the immunosuppressive circuits that undermine an effective antitumor immune response. In this review, the best characterized mechanisms that allow cancer cells to evade immune surveillance are overviewed and the most debated controversies constellating this complex field are highlighted.

Citing Articles

Immune checkpoint inhibitors in metastatic melanoma therapy (Review).

Shah V, Panchal V, Shah A, Vyas B, Agrawal S, Bharadwaj S Med Int (Lond). 2024; 4(2):13.

PMID: 38410760 PMC: 10895472. DOI: 10.3892/mi.2024.137.


Myeloid - derived suppressor cells in Type 1 diabetes are an expanded population exhibiting diverse T-cell suppressor mechanisms.

Grohova A, Danova K, Adkins I, Sumnik Z, Petruzelkova L, Obermannova B PLoS One. 2020; 15(11):e0242092.

PMID: 33206686 PMC: 7673497. DOI: 10.1371/journal.pone.0242092.


Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy.

Longhi G, Van Sinderen D, Ventura M, Turroni F Front Microbiol. 2020; 11:575072.

PMID: 33013813 PMC: 7507897. DOI: 10.3389/fmicb.2020.575072.


Harnessing the potential of multimodal radiotherapy in prostate cancer.

Philippou Y, Sjoberg H, Lamb A, Camilleri P, Bryant R Nat Rev Urol. 2020; 17(6):321-338.

PMID: 32358562 DOI: 10.1038/s41585-020-0310-3.


Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.

Koehn B, Saha A, McDonald-Hyman C, Loschi M, Thangavelu G, Ma L Blood. 2019; 134(19):1670-1682.

PMID: 31533918 PMC: 6871306. DOI: 10.1182/blood.2019001950.